United States set
Menu Shopping cart $0 Search
Distributed product

Anti-SARS-CoV-2 Antibody ELISA (S1RBD IgG)

  • Regulatory status:RUO
  • Type:ELISA
  • Other names:Severe acute respiratory syndrome coronavirus 2 nucleocapsid, 2019 novel coronavirus nucleoprotein, SARS-CoV-2 NP, SARS-CoV-2 N protein, COVID-19
  • Species:Human
Cat. No. Size Price

E111 96 wells (1 kit)
PubMed Product Details
Technical Data




Mediagnost anti-SARS-CoV-2 ELISA is a highly specific enzyme immunoassay for the detection of IgG antibodies directed against SARS-CoV-2-S1 Receptor Binding Domain (RBD) in human blood. The anti-SARS-CoV-2 ELISA is For Research Use Only. Not for use in diagnostic procedures. The product is intended for use by professional persons only.


Serum, Plasma-EDTA, Plasma-Heparin

Sample Requirements

5 µl/well


Upon receipt store the kit at 2–8°C. The shelf life of the components after initial opening is warranted for 4 weeks, store the unused strips and microtiter wells airtight together with the desiccant at 2–8°C in the clip-lock bag, use in the frame provided. The 1:20 diluted Washing Buffer WP is stable at 2–8°C for 4 weeks.

Intra-assay (Within-Run)

n = 30
CV = < 10%

Inter-assay (Run-to-Run)

n = 53
CV = < 12%



  • It is intended for research use only.
  • The total assay time is less than 3 hours.
  • The kit detects IgG antibodies directed against SARS-CoV-2-S1 Receptor Binding Domain (RBD) in human serum or plasma.
  • Assay format is 96 wells.
  • The microtiter plater is coated with eukaryotic expressed recombinant SARS-CoV-2 S1RBD.
  • Positive control serum and negative control serum are included with the kit.

Research topic



In December 2019 a novel coronavirus SARS-CoV-2 was identified in Wuhan, China and was announced as the causative agent for COVID-19 disease. The incubation period of the disease is 2-14 days. Symptoms of COVID-19 include fever, fatigue and cough, shortness of breath, muscle pain and tiredness. Most of the infected persons have a good prognosis, some of severe cases may have pneumonia, severe acute respiratory distress or even succumb to the disease.

The entry process of SARS-CoV-2 to the host cell is mediated by the envelope-embedded surface-located spike glycoprotein S. The protein is cleaved by host proteases into the S1 and S2 subunits, which are responsible for receptor recognition and membrane fusion, respectively. As target antigen of the assay the recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 S1 spike protein, which binds the ACE2 receptor, is used. The use of RBD increases the specificity of the assay since the domain is identical with SARS-CoV but not with MERS-CoV for example. Antibodies directed against the RBD neutralize both virus strains SARS-CoV and SARS-CoV-2.

Up to now there are seven coronaviruses described which can infect humans. Two of them are alpha coronaviruses (229E, NL63) and five are beta coronaviruses (OC43, HKU1, MERS-CoV, SARS-CoV, SARS-CoV-2).

Mediagnost anti-SARS-CoV-2 ELISA E111 is a two-step enzyme-linked immunosorbent assay. Wells of a 96-well microtiter plate are coated with recombinant SARS-CoV-2 Spike protein S1 (RBD). After addition of human serum or plasma samples anti-S1 IgG antibodies from the sample bind to the immobilized antigen during a two hours incubation followed by several washing steps in order to remove unbound components. The bound anti-SARS-CoV-2 IgG antibodies are detected by incubation with HRP conjugated anti-human IgG for 30 minutes. Subsequently, an HRP substrate solution containing 3,3’,5,5’-Tetramethylbenzidine (TMB) is added resulting in the formation of a blue colour. The reaction is terminated by the addition of 0.2 M H2SO4 changing the blue colour into yellow signals which are measured by an absorbance microtiter plate reader at 450 nm. The extinction increases with the amount of the captured antibodies directed against SARS-CoV-2-S1 (RBD) from the infected person´s sera.

Product References (2)


  • Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 Jun;17(6):613-620. doi: 10.1038/s41423-020-0400-4. Epub 2020 Mar 19. PubMed PMID: 32203189. PubMed CentralPMCID: PMC7091888. See more on PubMed
  • Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, Wang Q, Zhou H, Yan J, Qi J. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020 May 14;181(4):894-904.e9. doi: 10.1016/j.cell.2020.03.045. Epub 2020 Apr 9. PubMed PMID: 32275855. PubMed CentralPMCID: PMC7144619. See more on PubMed
Related Products Docs